Author/Authors :
Bilge, Mehmet Yıldırım Beyazıt University - Faculty of Medicine - Department of Cardiology, Turkey , Bilge, Mehmet Atatürk Education and Research Hospital - Clinic of Cardiology, Turkey , Yaşar, Ayşe Saatcı Atatürk Education and Research Hospital - Clinic of Cardiology, Turkey , Alemdar, Recai Atatürk Education and Research Hospital - Clinic of Cardiology, Turkey , Ali, Sina Atatürk Education and Research Hospital - Clinic of Cardiology, Turkey
Abstract :
Transcatheter aortic valve implantation (TAVI) is a new therapeutic option for inoperable/high risk patients with severe symptomatic calcific aortic stenosis (AS). The only admitted indication for TAVI is the treatment of patients with symptomatic severe calcific AS. However, some reports suggested feasibility and good short-term results with ‘‘off-label’’ uses of TAVI in patients with degenerated aortic bioprostheses and aortic regurgitation (1-3).
